NEW YORK (GenomeWeb) – NeoGenomics today reported that its fourth quarter revenues increased 36 percent with growth driven by both organic operations and its July 2014 acquisition of PathLogic.

The Ft. Myers, Fla.-based molecular testing clinical lab reported total revenues of $25 million for the three months ended Dec. 31, up from $18.3 million for the fourth quarter of 2013. It beat analysts' consensus estimate of $24.3 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers are refining a tool to predict a woman's risk of developing breast cancer, according to the Guardian.

According to Stat News, the partial government shutdown in the US could soon affect the ability of the Food and Drug Administration to review new drugs.

In PNAS this week: gypsy moth genome sequenced, phylogenomic analysis of Polyneopterans, and more.

CNN reports that people's genes tend to have a greater influence on their risk of developing disease than their environment, but it varies by phenotype.